Nitrefazole

Summary

Nitrefazole (CHEMBL1909285) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 248.19 Da · C10H8N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1909285
Name	Nitrefazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71900
Molecular formula	C10H8N4O4
Molecular weight	248.19
InChIKey	NMTBSNPBIGRZBL-UHFFFAOYSA-N

SMILES: CC1=NC(=CN1C2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]

IUPAC name: 2-methyl-4-nitro-1-(4-nitrophenyl)imidazole

Also known as: EMD 15 700, Nitrefazol, Nitrefazole, nitrefazole, SID144206859, NITREFAZOLE

Patent coverage: 40 distinct patent families (155 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).